Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort

Journal of Viral Hepatitis

Volumn 16, Issue 11, 2009, Pages 802-813

  Thein, H H ^b,c   Yi, Q ^d   Heathcote, E J ^e   Krahn, M D ^a,b,f  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Canadian Blood Service   (United States)

^e TORONTO WESTERN HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cirrhosis; Decision making; Hepatitis C; Markov model; Natural history; Transfusion acquired

Indexed keywords

ARTICLE; COMPENSATION; CONTROLLED STUDY; FEMALE; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; POSTTRANSFUSION HEPATITIS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; CANADA; COHORT STUDIES; COMPENSATION AND REDRESS; FEMALE; HEMOPHILIA A; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, THEORETICAL; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 70350003605     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01136.x     Document Type: Article

References (90)

1. Seeff LB. Natural history of hepatitis C. Hepatology 1997 26 : 21S 28S.
2. Seeff LB. Natural history of hepatitis C. Am J Med 1999 107 : 10S 15S.
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002 36 : S35 S46.
4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989 244 : 359 362.
5. Tobler LH, Busch MP. History of posttransfusion hepatitis. Clin Chem 1997 43 : 1487 1493.
6. Kuo G, Choo QL, Alter HJ et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989 244 : 362 364.
7. Stevens CE, Taylor PE, Pindyck J et al. Epidemiology of hepatitis C virus. A preliminary study in volunteer blood donors. JAMA 1990 263 : 49 53.
8. Comeau P. Hepatitis C compensation may be extended. CMAJ 2005 172 : 25.
9. Witkos M, Yi Q, Heathcote J, Kapral MK, Krahn M. Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients. Can J Gastroenterol 2006 20 : 107 111.
10. Krahn M, Wang P, Yi Q, Scully L, Sherman M, Heathcote EJ. Estimating the Prognosis of Canadians Infected with the Hepatitis C Virus Through the Blood Supply, 1986-1990 - Second Revision of Prognostic Model Incorporating Data from the Compensation Claimant Cohort. Toronto : University Health Network, 2005.
11. Krahn M, Wong JB, Heathcote J, Scully L, Seeff L. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making 2004 24 : 20 29.
12. Wang P, Yi Q, Scully L, Heathcote J, Krahn M. Indications for interferon/ribavirin therapy in hepatitis C patients: findings from a survey of Canadian hepatologists. Can J Gastroenterol 2003 17 : 183 186.
13. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997 349 : 825 832.
14. Poynard T, Ratziu V, Benmanov Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 2000 20 : 47 55.
15. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994 20 : 15 20.
16. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24 : 289 293.
17. TreeAge Software I. Data Pro for Health Care User's Manual. Williamstown, MA : TreeAge Software, INC., 2001.
18. Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004 40 : 860 867.
19. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003 38 (Suppl. 1 S38 S53.
20. Friedman SL, Bansal MB. Reversal of hepatic fibrosis - fact or fantasy? Hepatology 2006 43 : S82 S88.
21. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002 122 : 1303 1313.
22. Vamvakas EC, Taswell HF. Long-term survival after blood transfusion. Transfusion 1994 34 : 471 477.
23. Vamvakas EC, Moore SB. Length of survival after perioperative transfusion. Transfus Med 1997 7 : 115 121.
24. Poynard T, McHutchison J, Davis GL et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000 32 : 1131 1137.
25. Sobesky R, Mathurin P, Charlotte F et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999 116 : 378 386.
26. Goedert JJ, Eyster ME, Lederman MM et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002 100 : 1584 1589.
27. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001 183 : 1112 1115.
28. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994 87 : 555 561.
29. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998 17 : 2265 2281.
30. Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol 2003 92 : 1447 1451.
31. Chen W, Wong T, Tomlinson G, Krahn M, Heathcote EJ. Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic. J Hepatol 2008 49 : 711 717.
32. Potosky AL, Legler J, Albertsen PC et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000 92 : 1582 1592.
33. Rosenbaum PR. Discussing hidden bias in observational studies. Ann Intern Med 1991 115 : 901 905.
34. Rosenbaum PR, Rubin DB. Reducing Bias in Observational Studies Using Subclassification on the Propensity Score. J Am Stat Assoc 1984 79 : 516 524.
35. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006 13 : 34 41.
36. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997 26 : 15S 20S.
37. Krahn M, Thein HH, Yi Q. Estimating the Prognosis of Canadians Infected with the Hepatitis C Virus Through the Blood Supply, 1986-1990 - Third Revision of Hepatitis C Prognostic Model Incorporating Data from the Compensation Claimant Cohort. Toronto : University Health Network, 2008.
38. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology 2005 42 : 711 723.
39. Bralet MP, Regimbeau JM, Pineau P et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000 32 : 200 204.
40. Yatsuhashi H, Yano M. Natural history of chronic hepatitis C. J Gastroenterol Hepatol 2000 15 : E111 E116.
41. Krahn M, Heathcote J, Scully L, Seeff L, Wong J. Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada Between 1986 and 1990. Toronto : University Health Network, 1999.
42. Kim WR, Poterucha JJ, Benson JT, Therneau TM. The impact of competing risks on the observed rate of chronic hepatitis C progression. Gastroenterology 2004 127 : 749 755.
43. Arnold DM, Julian JA, Walker IR. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood 2006 108 : 460 464.
44. Darby SC, Kan SW, Spooner RJ et al. The impact of HIV on mortality rates in the complete UK haemophilia population. AIDS 2004 18 : 525 533.
45. Darby SC, Ewart DW, Giangrande PL et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997 350 : 1425 1431.
46. Soucie JM, Nuss R, Evatt B et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000 96 : 437 442.
47. Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000 47 : 845 851.
48. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003 362 : 2095 2100.
49. Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000 132 : 517 524.
50. Nishiguchi S, Shiomi S, Nakatani S et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001 357 : 196 197.
51. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004 292 : 2839 2848.
52. Chung RT, Andersen J, Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004 351 : 451 459.
53. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
54. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
55. Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004 18 : F27 F36.
56. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004 351 : 438 450.
57. Alfaleh FZ, Hadad Q, Khuroo MS et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004 24 : 568 574.
58. Bosques-Padilla F, Trejo-Estrada R, Campollo-Rivas O et al. Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Ann Hepatol 2003 2 : 135 139.
59. Gish RG, Arora S, Rajender Reddy K et al. Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 2007 47 : 51 59.
60. Krawitt EL, Gordon SR, Grace ND et al. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2006 101 : 1268 1273.
61. Crespo M, Sauleda S, Esteban JI et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007 14 : 228 238.
62. Helbling B, Jochum W, Stamenic I et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006 13 : 762 769.
63. Lee SD, Yu ML, Cheng PN et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005 12 : 283 291.
64. Mimidis K, Papadopoulos VP, Elefsiniotis I et al. Hepatitis C virus survival curve analysis in naive patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. J Gastrointestin Liver Dis 2006 15 : 213 219.
65. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
66. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999 30 : 1054 1058. (Pubitemid 29458296)
67. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008 22 : 1979 1991.
68. Sweeting MJ, De Angelis D, Neal KR et al. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol 2006 59 : 144 152.
69. Seeff LB, Hollinger FB, Alter HJ et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001 33 : 455 463.
70. Hamada H, Yatsuhashi H, Yano K et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer 2002 95 : 331 339.
71. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995 332 : 1463 1466.
72. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000 32 : 582 587.
73. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008 48 : 418 431.
74. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997 127 : 855 865.
75. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000 90 : 1562 1569.
76. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999 29 : 1596 1601.
77. Law MG, Dore GJ, Bath N et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol 2003 32 : 717 724.
78. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002 156 : 761 773.
79. Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993 13 : 274 278.
80. Vogt M, Lang T, Frosner G et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999 341 : 866 870.
81. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999 340 : 1228 1233.
82. Alter MJ, Margolis HS, Krawczynski K et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992 327 : 1899 1905.
83. Barrera JM, Bruguera M, Ercilla MG et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995 21 : 639 644.
84. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000 284 : 450 456.
85. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999 29 : 908 914.
86. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology 2000 32 : 91 96.
87. Sweeting MJ, De Angelis D, Brant LJ, Harris HE, Mann AG, Ramsay ME. The burden of hepatitis C in England. J Viral Hepat 2007 14 : 570 576.
88. Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998 28 : 823 830.
89. Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996 334 : 815 820.
90. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997 112 : 463 472.